Other approaches. In 2011, the biopharmaceutical company Sutro Biopharma formed a multiyear collaboration with Pfizer for the research, development
and commercialisation of novel peptidebased therapeutics. The partnership gives Pfizer access to peptides that have been difficult
to produce using conventional technologies using a biochemical protein synthesis technology platform developed by Sutro.
In 2008, Pfizer acquired CovX, a biopharmaceutical company with a technology platform that links therapeutic peptides to an
antibody scaffold. The peptide targets the disease while the antibody scaffold allows the peptide to remain in the body long
enough to achieve therapeutic benefit. The technology thereby allows for better half-life extension and bioavailability to
support optimal dosing regimens for peptide therapeutics.
References
1. T. Sawyer, Chem. Biol. Drug. Des. 73 (1), 3–6 (2009).
2. W. Wolfson, Chem. & Biol. 16 (9), 910–911 (2009).
3. Peptide Therapeutics Foundation, Development Trends for Peptide Therapeutics Report (San Diego, 2010).
4. FDA, Copaxone Label (Feb. 27, 2009), Drugs@FDA, accessed May 15, 2012.
5. FDA, Lupron Label (Mar. 28, 2012), Drugs@FDA, accessed May 15, 2012.
6. FDA, Zoladex Label (Jan. 14, 2011), Drugs@FDA, accessed May 15, 2012.
7. FDA, Sandostain Label (Mar. 23, 2012), Drugs@FDA, accessed May 15, 2012.
8. FDA, Byetta Label (Oct. 19, 2011), Drugs@FDA, accessed May 15, 2012.
9. FDA, Forteo Label (July 26, 2009), Drugs@FDA, accessed May 15, 2012.
10. P. Van Arnum, Pharm. Technol.
35 (5), 56–60 (2011).
11. S. Bhattacharya et al., Biopolymers
97 (5), 253–264 (2012).
12. D. Ly et al., J. Am. Chem. Soc. 134 (9), 4041–4044 (2012).
|
